Crescent Biopharma, Inc.

NASDAQ:CBIO

Biotechnology

Healthcare
$12.40 -2.69%

-$0.49 today

Market cap
$482.30M
Beta
1.15
P/E (TTM)
-3.3
EPS (TTM)
-$5.33
52W Low $8.72High $27.41

Volume 0.33M

Average 0.28M

CBIO Net Income

Bottom-line profit after all expenses, interest, and taxes.

Crescent Biopharma, Inc.NASDAQ: CBIO

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income remains negative

Q1 FY2026 net income was -$23.28M, compared with -$15.15M a year earlier. Trailing-twelve-month net income was -$162.08M.

Context

  • Net income amounted to 1419.6% of revenue in FY2025.
  • Net income grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 5 analysts of -$35.26M (+77.1%) for the fiscal year ending Dec 2026, a step up from the -217.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$23.28M+74.8% QoQ
Last fiscal yearDec 2025
-$153.94M-217.3% YoY
LTMMar 2026
-$162.08M-206.2% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-53.7%-31.9%+21.8 pp
1 year-217.3%+77.1%+294.4 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
(153.94M) USD
Year-over-year change
-217.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How CBIO compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -206.2% is the 9th highest of 10, against a peer median of -26.1%.
  • Net income amounts to 1363.9% of revenue for CBIO, versus a peer median of 107.2%.
CBIO Competitors
Net Income for CBIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ZYMEZymeworks Inc.LTM Sep 2026$43.31M USD+168.3%—16.3%
CGENCompugen Ltd.LTM Mar 2026$34.86M USD+346.4%—48.0%
NBPNovaBridge BiosciencesLTM Sep 2025-CN¥24.54M CNY+92.4%——
CNTXContext Therapeutics Inc.LTM Mar 2026-$40.23M USD-45.6%——
CTMXCytomX Therapeutics, Inc.LTM Mar 2026-$59.14M USD-242.2%—166.4%
CMPXCompass Therapeutics, Inc.LTM Mar 2026-$68.17M USD-23.5%——
MGNXMacroGenics, Inc.LTM Mar 2026-$70.36M USD-26.1%—44.8%
CBIOCrescent Biopharma, Inc.LTM Mar 2026-$162.08M USD-206.2%—1363.9%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026-$309.11M USD-37.7%—275986.6%
RCUSArcus Biosciences, Inc.LTM Jun 2026-$452M USD-47.7%—386.3%
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding CBIO) —-26.1%—107.2%

Competitors are the stored peer set for CBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.16M75K10K010.84M
Cost of Revenue00000
Gross Profit1.16M75K10K010.84M
Gross Margin100.0%100.0%100.0%—100.0%
Research & Development47.49M28.39M20.07M28.06M138.09M
Selling, General & Admin17.12M19.09M19.21M16.32M25.39M
Operating Expenses64.61M47.48M39.29M49.9M163.48M
Depreciation & Amortization264.6K207.15K153.3K35.17K84K
EBITDA(63.18M)(47.2M)(39.12M)(44.17M)(149.67M)
EBITDA Margin-5447.9%-62927.6%-391213.5%—-1380.2%
Operating Income(63.45M)(47.4M)(39.28M)(49.9M)(152.63M)
Operating Margin-5470.7%-63204.4%-392752.9%—-1407.5%
Interest Income19.77K714.52K2.38M1M2.88M
Interest Expense000852K2.19M
Other Income / Expenses19.77K714.96K2.38M1.37M690K
Income Before Tax(63.43M)(46.69M)(36.9M)(48.52M)(151.94M)
Pre-Tax Margin-5469.0%-62251.1%-368987.8%—-1401.2%
Income Tax Expense00002M
Net Income(63.43M)(46.69M)(36.9M)(48.52M)(153.94M)
Net Margin-5469.0%-62251.7%-368994.2%—-1419.6%
EPS (Basic)(1.23)(0.89)(0.58)(1.40)(14.78)
EPS (Diluted)(1.23)(0.89)(0.58)(1.40)(14.78)
Weighted Avg Shares51.45M52.53M63.34M19.5M10.41M
Weighted Avg Shares (Diluted)51.45M52.53M63.34M19.5M10.41M

Crescent Biopharma, Inc.

NASDAQ:CBIO

Intrinsic Alpha fair value

Locked

Current Price

$12.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.